Fasting-Refedding Cycle for Obesity
(DIP Trial)
Trial Summary
What is the purpose of this trial?
The regulation of human body weight and fatness is not fully understood. Although some models of regulation have been proposed (set point, dual-intervention point, others), no studies have been designed to test their predictions. In this pilot and feasibility study, the investigators will implement an experimental approach to test the predictions of models of body weight regulation in humans. Men and women with either low body weight or obesity will be exposed to a 2-day fasting followed by a 2-day ad-libitum refeeding. During the entire fasting-refeeding period, energy intake and expenditure will be accurately measured within metabolic chambers. The investigators will therefore determine the compensatory responses to fasting elicited to prevent weight loss. The results will serve to design and power future studies to better understand body weight regulation.
Will I have to stop taking my current medications?
You may need to stop taking certain medications that affect energy intake or expenditure, like semaglutide or metformin, to participate in this trial. The protocol doesn't specify a washout period, but it's best to discuss with the trial team.
What data supports the effectiveness of the fasting-refeeding cycle treatment for obesity?
Is the fasting-refeeding cycle generally safe for humans?
The studies reviewed do not directly address the safety of fasting-refeeding cycles in humans, but they suggest that refeeding after fasting can help maintain weight loss and improve eating behavior. However, the long-term effects and safety in humans are not clearly established, and more research is needed to understand potential risks.56789
How does the fasting-refeeding cycle treatment for obesity differ from other treatments?
The fasting-refeeding cycle treatment for obesity is unique because it involves alternating periods of fasting and eating freely, which can lead to increased food efficiency and rapid weight regain due to the body's energy conservation mechanisms. This approach contrasts with continuous caloric restriction, which often leads to long-term weight regain due to hormonal and metabolic changes.168910
Research Team
Rodrigo Fernandez-Verdejo, PhD
Principal Investigator
Pennington Biomedical Research Center
Eric Ravussin, PhD
Principal Investigator
Pennington Biomedical Research Center
Dragana Lovre, MD
Principal Investigator
Tulane University
Eligibility Criteria
This trial is for men and women aged 20-40 with stable body weight who are either underweight (BMI < 18.5) or obese (BMI ≥ 30). Participants must have normal thyroid, blood count, and chemistry levels, enjoy Ensure Plus drinks to some extent, and women should not have given birth and must have regular menstrual cycles.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Inpatient Energy Balance
Participants are maintained in metabolic chambers for 1 day of energy balance
Fasting
Participants undergo 2 days of fasting to measure compensatory responses
Ad-libitum Refeeding
Participants undergo 2 days of ad-libitum refeeding to measure compensatory responses
Follow-up
Participants are monitored for safety and effectiveness after the fasting-refeeding cycle
Treatment Details
Interventions
- Fasting-refeeding cycle
Find a Clinic Near You
Who Is Running the Clinical Trial?
Pennington Biomedical Research Center
Lead Sponsor
Tulane University
Collaborator